307 related articles for article (PubMed ID: 34407065)
1. Genome-Wide Profiling of Alternative Splicing Signatures Associated with Prognosis and Immune Microenvironment of Hepatocellular Carcinoma.
Liu Z; Ye J; Khan AA; Chen J; Zhou L; Zheng S; Xu X
Med Sci Monit; 2021 Aug; 27():e930052. PubMed ID: 34407065
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
3. Profiles of prognostic alternative splicing signature in hepatocellular carcinoma.
Wu F; Chen Q; Liu C; Duan X; Hu J; Liu J; Cao H; Li W; Li H
Cancer Med; 2020 Mar; 9(6):2171-2180. PubMed ID: 31975560
[TBL] [Abstract][Full Text] [Related]
4. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
Zhang D; Duan Y; Wang Z; Lin J
Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
[TBL] [Abstract][Full Text] [Related]
5. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
Lai J; Yang H; Xu T
BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
[TBL] [Abstract][Full Text] [Related]
6. Construction of a novel immune-related lncRNA signature and its potential to predict the immune status of patients with hepatocellular carcinoma.
Deng M; Lin JB; Zhao RC; Li SH; Lin WP; Zou JW; Wei W; Guo RP
BMC Cancer; 2021 Dec; 21(1):1347. PubMed ID: 34923955
[TBL] [Abstract][Full Text] [Related]
7. Novel insights into clear cell renal cell carcinoma prognosis by comprehensive characterization of aberrant alternative splicing signature: a study based on large-scale sequencing data.
Zhang D; Zhang W; Sun R; Huang Z
Bioengineered; 2021 Dec; 12(1):1091-1110. PubMed ID: 33783315
[TBL] [Abstract][Full Text] [Related]
8. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
Xu L; Zheng Q; Liu W
BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
[TBL] [Abstract][Full Text] [Related]
9. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
10. Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data.
Wu HY; Peng ZG; He RQ; Luo B; Ma J; Hu XH; Dang YW; Chen G; Pan SL
Int J Oncol; 2019 Aug; 55(2):425-438. PubMed ID: 31268164
[TBL] [Abstract][Full Text] [Related]
11. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
12. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.
Yu S; Cai L; Liu C; Gu R; Cai L; Zhuo L
Mol Med; 2021 Apr; 27(1):36. PubMed ID: 33832428
[TBL] [Abstract][Full Text] [Related]
13. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
15. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma.
Sun XY; Yu SZ; Zhang HP; Li J; Guo WZ; Zhang SJ
Cancer Med; 2020 Apr; 9(8):2868-2878. PubMed ID: 32068352
[TBL] [Abstract][Full Text] [Related]
16. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
17. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
Front Immunol; 2021; 12():719175. PubMed ID: 34603293
[TBL] [Abstract][Full Text] [Related]
18. Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification.
Ouyang G; Li Q; Wei Y; Dai W; Deng H; Liu Y; Li J; Li M; Luo S; Li S; Liang Y; Pan G; Yang J; Gan T
Front Immunol; 2024; 15():1323199. PubMed ID: 38742112
[TBL] [Abstract][Full Text] [Related]
19. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
20. Normal tissue adjacent to tumor expression profile analysis developed and validated a prognostic model based on Hippo-related genes in hepatocellular carcinoma.
Pan Q; Qin F; Yuan H; He B; Yang N; Zhang Y; Ren H; Zeng Y
Cancer Med; 2021 May; 10(9):3139-3152. PubMed ID: 33818013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]